Physician profile
Matthew E Dauterive
NPI 1053679530
$7,935.93
in general payments reported to CMS, 2019-2025
34 companies · $863 in 2025
The $863 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,744 · 2020: $1,262 · 2021: $1,472 · 2022: $1,500 · 2023: $644 · 2024: $452 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,842 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,841.71 |
| Education | $116.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,434.89 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,066.27 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Genzyme Corporation | $693.29 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $560.29 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $551.37 | 2019-2025 | Dupixent |
| Insmed, INC. | $350.14 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $231.60 | 2019-2023 | Opsumit |
| Genentech USA, INC. | $221.38 | 2019 | |
| Mylan Specialty L.P. | $205.98 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $193.96 | 2021-2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $180.10 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.68 | 2021-2022 | |
| Grifols USA, LLC | $131.41 | 2020-2022 | |
| Amgen INC. | $127.42 | 2022-2025 | Tezspire |
| Gilead Sciences, INC. | $115.25 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $104.18 | 2019-2022 | |
| United Therapeutics Corporation | $85.20 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $55.53 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $51.11 | 2021 | |
| Viatris Specialty LLC | $48.31 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $44.18 | 2021 | |
| Getinge USA Sales, LLC | $43.67 | 2019 | |
| Verona Pharma, INC. | $43.66 | 2025 | Ohtuvayre |
| Ceribell, INC. | $41.17 | 2024-2025 | Pocket Eeg Device |
| Fisher & Paykel Healthcare INC | $30.44 | 2021 | |
| Pfizer INC. | $25.21 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.87 | 2020 | |
| Sunovion Pharmaceuticals INC. | $20.46 | 2019 | |
| Acacia Pharma INC | $20.30 | 2021 | |
| Pulmonx Corporation | $20.26 | 2021 | |
| Merit Medical Systems INC | $18.09 | 2022 | |
| Astellas Pharma US INC | $17.77 | 2021 | |
| Phadia US INC. | $16.70 | 2022 | |
| Ekos Corporation | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Dauterive listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.